Efficacy and safety of Efgartigimod in patients with generalized myasthenia gravis: interim results of a prospective, single-arm, observational study in China

被引：0
|
作者：
Liang, H. [1 ]
Wang, P. [1 ]
Zhang, B. [1 ]
Zhao, C. [2 ]
Huang, S. [1 ]
机构：
[1] Hainan Med Univ, Hainan Affiliated Hosp, Dept Neurol, Hainan Gen Hosp, Haikou, Peoples R China
[2] Fudan Univ, Dept Neurol, Huashan Rare Dis Ctr, Huashan Hosp, Shanghai, Peoples R China
来源：
NEUROMUSCULAR DISORDERS | 2023年 / 33卷
关键词：
D O I：
10.1016/j.nmd.2023.07.437
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
VP270
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [31] Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT plus study
    Bril, Vera
    Pasnoor, Mamatha
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said
    Vu, Tuan
    Ulrichts, Peter
    Van Hoorick, Benjamin
    T'Joen, Caroline
    Kaprielian, Roger
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    Howard, James F., Jr.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [32] Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT plus ): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
    Howard Jr, James F.
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Meisel, Andreas
    Beydoun, Said R.
    Pasnoor, Mamatha
    Guglietta, Antonio
    Van Hoorick, Benjamin
    Steeland, Sophie
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    FRONTIERS IN NEUROLOGY, 2024, 14
  • [33] TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY
    Howard, J.
    Vu, T.
    Bril, V.
    Peric, S.
    Verschuuren, J.
    Mantegazza, R.
    Murai, H.
    Ulrichts, P.
    Guglietta, A.
    de Haard, H.
    Parys, W.
    Beydoun, S.
    Pasnoor, M.
    Karam, C.
    Muppidi, Sr
    Bertorini, T.
    Bhavaraju-Sanka, R.
    Li, Y.
    MUSCLE & NERVE, 2020, 62 : S125 - S126
  • [34] SAFETY AND EFFICACY OF SUBCUTANEOUS IMMUNOGLOBULIN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Katzberg, Hans
    Idiaquez, Juan
    Mendoza, Meg
    Barnett, Carolina
    Huszti, Ella
    Lovblom, Erik
    Wang, Stella
    Bril, Vera
    MUSCLE & NERVE, 2024, 70 (03) : 683 - 683
  • [35] Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis
    Ruan, Zhe
    Tang, Yonglan
    Gao, Ting
    Li, Chunhong
    Guo, Rongjing
    Sun, Chao
    Huang, Xiaoxi
    Li, Zhuyi
    Chang, Ting
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (06)
  • [36] Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients
    Nomura, Toshiya
    Imamura, Michie
    Imura, Masao
    Mizutani, Hironori
    Ueda, Mitsuharu
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [37] Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study
    Zhu, Geke
    Zhou, Han
    Wang, Wanying
    Ma, Yongbo
    Nie, Xiangtao
    Qi, Wenjing
    Hao, Lei
    Guo, Xiuming
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2025, 18
  • [38] EFFICACY AND SAFETY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS - A PROSPECTIVE CASE SERIES
    Siddiqi, Zaeem A.
    Blackmore, Derrick
    Alvi, Muhammad
    Hussain, Faraz
    MUSCLE & NERVE, 2022, 65 : S40 - S40
  • [39] EXAMINATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY SERONEGATIVE PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: SUBGROUP ANALYSIS OF PHASE 3
    Howard, James
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    De Bleecker, Jan L.
    Murai, Hiroyuki
    Pasnoor, Mamatha
    Sacca, Francesco
    Meisel, Andreas
    Guglietta, Antonio
    T'joen, Caroline
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    MUSCLE & NERVE, 2021, 64 : S5 - S5
  • [40] Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.
    Hu, Shiwei
    Yang, Xiudi
    Tong, Hongyan
    Jin, Jie
    Huang, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345